The News on Drug Prices? Nothing Good
From the article:
“It takes away a substantial tool that a lot of states were hoping to use,” says Rachel Sachs, a law professor and drug policy expert at Washington University in St. Louis. It also points to a hypocrisy, she says. “They’re permissive when it comes to work requirements that put added burden on the vulnerable, but protective when it comes to measures that would strain the pharmaceutical industry.”
It’s unclear where we go from here. The administration’s road map for lowering drug costs was short on details about when or how any of its provisions might take effect. And while there’s no telling what Mr. Trump discussed with Pfizer that caused it to temporarily halt planned price increases, the exchanges between Mr. Cohen and Novartis hardly inspire good faith. In fact, if the industry is “getting away with murder,” as Mr. Trump once claimed, it stands to reason that at this point, it’s doing it with the president’s help.
Read more here!
Read the full article
Tags
fda health care finance health law policy pharmaceuticals rachel sachs regulation